Mestranol (Devocin, Ovastol, Tranel) (component of Enovid, Enavid, Ortho-Novin, Femigen, Norbiogest) – the 3-methyl ether ofethinylestradiol
Moxestrol (Surestryl) – the 11β-methoxy derivative ofethinylestradiol (and hence the 11β-methyl ether of the 11β-hydroxyl derivative of ethinylestradiol)
^Ferin, J. (1952). "Relative duration of action of natural and synthetic estrogens administered parenterally in women with estrogen deficiency".The Journal of Clinical Endocrinology & Metabolism.12 (1):28–35.doi:10.1210/jcem-12-1-28.ISSN0021-972X.PMID14907837.
^Elger W, Wyrwa R, Ahmed G, Meece F, Nair HB, Santhamma B, Killeen Z, Schneider B, Meister R, Schubert H, Nickisch K (January 2017). "Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions".J. Steroid Biochem. Mol. Biol.165 (Pt B):305–311.doi:10.1016/j.jsbmb.2016.07.008.PMID27449818.S2CID26650319.
^Ahmed G, Elger W, Meece F, Nair HB, Schneider B, Wyrwa R, Nickisch K (October 2017). "A prodrug design for improved oral absorption and reduced hepatic interaction".Bioorg. Med. Chem.25 (20):5569–5575.doi:10.1016/j.bmc.2017.08.027.PMID28886996.
^Nickisch, K., Santhamma, B., Ahmed, G., Meece, F., Elger, W., Wyrwa, R., & Nair, H. (2017).U.S. Patent No. 9,745,338. Washington, DC: U.S. Patent and Trademark Office.https://patents.google.com/patent/US9745338B2/en
^Vizzone, A.; Murari, G. (November 1966). "[Estradiol esters (3-monobenzoate and 3-benzoate-17-beta-acetate) in the therapy of the surgical menopause syndrome. Experimental and clinical results]".Quaderni di Clinica Ostetrica e Ginecologica.21 (11):779–790.PMID5999221.
^abcLokind, Kenneth B.; Lorenzen, Finn Hjort; Bundgaard, Hans (1991). "Oral bioavailability of 17β-estradiol and various ester prodrugs in the rat".International Journal of Pharmaceutics.76 (1–2):177–182.doi:10.1016/0378-5173(91)90356-S.ISSN0378-5173.
^abFalconi G, Galletti F, Celasco G, Gardi R (November 1972). "Oral long-lasting estrogenic activity of estradiol 3-benzoate 17-cyclooctenyl ether".Steroids.20 (5):627–38.doi:10.1016/0039-128X(72)90020-7.PMID4654978.
^Galletti F, Gardi R (April 1974). "Effect of two orally active estradiol derivatives on sulfobromphthalein retention in rats".Pharmacol Res Commun.6 (2):135–45.doi:10.1016/s0031-6989(74)80021-4.PMID4438394.
^Janocko, Laura; Larner, Janice M.; Hochberg, Richard B. (1984). "The Interaction of C-17 Esters of Estradiol with the Estrogen Receptor*".Endocrinology.114 (4):1180–1186.doi:10.1210/endo-114-4-1180.ISSN0013-7227.PMID6705734.
^Dahlgren E, Crona N, Janson PO, Samsioe G (1985). "Oral replacement with estradiol-cyclooctyl acetate: a new estradiol analogue. Effects on serum lipids, proteins, gonadotrophins, estrogens and uterine endometrial morphology".Gynecol. Obstet. Invest.20 (2):84–90.doi:10.1159/000298978.PMID3932144.
^Luisi M, Kicovic PM, Alicicco E, Franchi F (1978). "Effects of estradiol decanoate in ovariectomized women".J. Endocrinol. Invest.1 (2):101–6.doi:10.1007/BF03350355.PMID755846.S2CID38187367.
^abGleason CH, Parker JM (1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17α-hydroxy-progesterone-17-heptanoate".Endocrinology.65 (3):508–511.doi:10.1210/endo-65-3-508.ISSN0013-7227.PMID13828402.
^abElger W, Palme HJ, Schwarz S (April 1998). "Novel oestrogen sulfamates: a new approach to oral hormone therapy".Expert Opin Investig Drugs.7 (4):575–89.doi:10.1517/13543784.7.4.575.PMID15991994.
^Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B (December 1995). "Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application".J. Steroid Biochem. Mol. Biol.55 (3–4):395–403.doi:10.1016/0960-0760(95)00214-6.PMID8541236.S2CID31312.
^Patel JU, Prankerd RJ, Sloan KB (October 1994). "A prodrug approach to increasing the oral potency of a phenolic drug. 1. Synthesis, characterization, and stability of an O-(imidomethyl) derivative of 17 beta-estradiol".J Pharm Sci.83 (10):1477–81.doi:10.1002/jps.2600831022.PMID7884673.
^Patel J, Katovich MJ, Sloan KB, Curry SH, Prankerd RJ (February 1995). "A prodrug approach to increasing the oral potency of a phenolic drug. Part 2. Pharmacodynamics and preliminary bioavailability of an orally administered O-(imidomethyl) derivative of 17 beta-estradiol".J Pharm Sci.84 (2):174–8.doi:10.1002/jps.2600840210.PMID7738796.